Cyclophosphamide Dosing Adjusted for Age and Renal Function
For oral cyclophosphamide, use 2 mg/kg/day (maximum 150 mg) with dose reduction to 50-100% of normal for eGFR 10-30 ml/min and contraindicated for eGFR <10 ml/min; for IV pulse therapy, use 15 mg/kg or 0.6 g/m² (maximum 1.2 g) for the first 3 infusions every 2 weeks, then 15 mg/kg or 0.7 g/m² every 3 weeks for pulses 3-6, with mandatory dose adjustment for renal impairment and age ≥65 years requiring lower doses to avoid toxicity.
Oral Cyclophosphamide Dosing
Standard Dosing by Indication
For vasculitis and glomerulonephritis:
- Standard dose: 2 mg/kg/day orally (maximum 150 mg/day) 1
- Alternative regimen: 1.5-2 mg/kg/day for 12 months in membranous nephropathy 2
- Duration: Typically 8-12 weeks for nephrotic syndrome, up to 3-6 months for vasculitis 1, 3
For malignant diseases:
- Range: 1-5 mg/kg/day orally for both initial and maintenance therapy 4
- Adjust based on antitumor activity and myelosuppression
Renal Function Adjustments for Oral Dosing
The 2025 British Society for Rheumatology guideline provides the most current renal dosing framework 5:
eGFR 30-50 ml/min:
- Use normal dose initially, but monitor closely
- Some sources recommend 75-100% of normal dose for eGFR 20-50 5
eGFR 10-30 ml/min:
eGFR <10 ml/min:
- Contraindicated per most guidelines 5
- If benefits outweigh risks, start at very low dose with intensive monitoring
Critical threshold: Avoid cyclophosphamide when serum creatinine ≥3.5 mg/dL or eGFR ≤30 ml/min/1.73 m² in glomerulonephritis, as risks outweigh benefits 2
Intravenous Pulse Cyclophosphamide Dosing
Standard IV Pulse Regimen
The EGPA consensus provides the most detailed IV dosing algorithm 1:
Initial 3 pulses (weeks 0,2,4):
- 15 mg/kg or 0.6 g/m² IV every 2 weeks
- Maximum single dose: 1.2 g 1
Subsequent pulses 3-6 (weeks 7,10,13):
- 15 mg/kg or 0.7 g/m² IV every 3 weeks
- Maximum single dose: 1.2 g 1
Alternative low-dose regimen:
Renal Function Adjustments for IV Dosing
eGFR >50 ml/min:
- Use standard doses as above 1
eGFR 30-50 ml/min:
eGFR <30 ml/min:
Age-Based Dose Modifications
Elderly Patients (≥65 Years)
Critical principle: Patients ≥65 years require lower immunosuppressant doses regardless of poor-prognosis factors to avoid drug-related side effects 1.
Specific adjustments:
- Consider reducing standard doses by 25-50% in patients >65 years
- The CORTAGE trial demonstrated benefit of lower doses in elderly patients 1
- Age >65 years is itself a poor prognostic factor in vasculitis (Five-Factor Score) 1
Practical approach for elderly:
- Start with 1.5 mg/kg/day oral or 500 mg/m² IV pulses
- Titrate based on tolerance and white blood cell counts
- More frequent monitoring required (CBC every 1-2 weeks initially)
Pediatric Patients
For minimal change nephrotic syndrome:
- 2 mg/kg/day orally for 8-12 weeks 3, 4
- Maximum cumulative dose: 168 mg/kg 3
- Treatment beyond 90 days increases sterility risk in males 4
Monitoring and Safety Considerations
Mandatory Monitoring
Before each dose:
- Complete blood count with differential
- Do not administer if neutrophils ≤1,500/mm³ or platelets <50,000/mm³ 4
During treatment:
- CBC every 2 weeks during oral therapy 3
- Renal function (creatinine, eGFR) quarterly 5
- Urinalysis for hemorrhagic cystitis
Cumulative Dose Limits
Maximum lifetime exposure:
- 25-36 g cumulative dose to minimize malignancy risk 8
- For fertility preservation: limit to 10 g cumulative 8
- Calculate cumulative dose: (daily dose × days) or (pulse dose × number of pulses)
Critical Safety Measures
Hydration protocol:
- Force diuresis during and immediately after administration 4
- Take oral doses in the morning to allow daytime voiding 4
Infection prophylaxis:
- Trimethoprim-sulfamethoxazole 400 mg daily or 800 mg three times weekly for Pneumocystis jiroveci prophylaxis 1
- Consider G-CSF for primary/secondary neutropenia prophylaxis 4
Fertility preservation:
Common Pitfalls to Avoid
Using Cockcroft-Gault instead of eGFR: Modern guidelines recommend BSA-adjusted eGFR (CKD-EPI 2021) for dosing decisions 5, 9
Ignoring age-related dose reduction: Elderly patients require lower doses even with normal renal function 1
Exceeding maximum single IV dose: Never exceed 1.2 g per infusion regardless of calculated dose 1
Inadequate hydration: Failure to force diuresis increases hemorrhagic cystitis risk 4
Missing cumulative dose tracking: Exceeding 36 g lifetime increases malignancy risk substantially 8
Dosing in severe renal impairment: Cyclophosphamide should generally be avoided when eGFR <30 ml/min unless benefits clearly outweigh risks 2